Editor’s Note April 24, 2012
This week, OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences with Dr. Shi of […]
Uncategorized
Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Dr. Shi of EdgeTech Law: Despite Mayo Clinic v. Prometheus “Setback,” Opportunities in Life Sciences Remain
OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences.
Biovest CEO and Sr. Vice President Discuss Global Marketing of BiovaxID
Biovest International, Inc. (OTCQB: BVTI) announced that Biovest is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.
Epigenomics Enrolls First Participant in its FIT Comparative Study with Epi proColon®
OneMedRadio interviewed Thomas Taapken, CFO of Epigenomics, a Berlin based molecular diagnostics company for the early detection of cancer.
PTSD Special Report: Part I, How to Curb a Potential Epidemic
In response to a recent press release from TONIX Pharmaceuticals, a leading company in the exploration of alternative PTSD treatment, we are issuing a 2-part special report looking at recent developments
Editor’s Note April 10, 2012
This week, OneMedPlace brings you parts II and III on patent infringement highlighting two more cases changing the landscape. OneMedRadio brings you three interviews in this issue. Dr. Steve […]
Patent Infringement Special Report: Part III, the Future of Drug Development
Part Three of our Special Report analyzes what may be one of the first ‘test cases’ of the new patent infringement precedent.